Short Communication: Management of TB in the wake of MDR-TB and XDR-TB in sub-Saharan Africa: how prepared are we? by Githui, Willie A.





MANAGEMENT OF TB IN THE WAKE OF MDR-TB AND XDR-TB IN SUB-SAHARAN AFRICA: HOW 
PREPARED ARE WE?  
Willie A. Githui, 
PhD Centre for Respiratory Diseases Research, Kenya medical Research Institute.P.O. Box 47855 00100-GPO, 
Nairobi, KenyaEmail:wgithui@yahoo.com  
[Afr J Health Sci. 2012; 20:91-83] 
 
Tuberculosis (TB) is an important public health 
problem worldwide. Several countries in the  African 
region bear  the brunt of the TB burden being among 
the 22 high TB burden countries with the incidence 
ranging between 150 and over 350 per 100,000 
population [WHO 2011]. Before the advent of 
HIV/AIDS, the incidence of TB was on the decline 
globally. Effective treatment is possible if TB infected 
persons are detected early and put on TB treatment 
immediately.  However, the arrival of HIV/AIDS has 
complicated the diagnosis and management of TB with 
associated emergence of MDR-TB and XDR-TB in the 
region.  
In this issue, several papers address pertinent TB issues 
from different parts of the African region. Three papers 
address the problem of drug resistance in Kenya. Two 
of these, by Asiko et al., specifically point out findings 
in retrospective studies involving well characterized 
archived isolates collected in the pre-MDR-TB era 
already indicating the emerging resistance in second 
line drugs namely ethionamide and the 
fluoroquinolones. This is an obvious course for 
concern to the TB control programme also reported in 
the third paper, by Ogaro et al., indicating high levels 
of drug resistant TB in Nairobi showing prevalence of 
0.54% and 8.54% MDR-TB of among new and 
previously treated patients, respectively. This is an 
indication that MDR TB in Kenya, like most African 
countries, is now a reality and the situation requires 
urgent and concerted effort to contain it. Spread of 
drug resistant strains of Mycobacterium tuberculosis 
and the management of patients diagnosed with drug 
resistant disease is one of the most formidable 
obstacles faced by national tuberculosis control 
programmes, compounded by a critical lack of 
appropriate diagnostic tools and vastly inadequate 
laboratory capacity. 
Conventional culture and DST methods [Canetti, 1969, 
Palomino, JC. 2008, 2010], require prolonged periods 
to confirm mycobacterial growth and detect drug 
resistance, during which time patients may be 
inappropriately treated, drug resistant strains may 
continue to spread, and amplification of resistance may 
occur. Rapid diagnosis of TB and drug resistance will 
therefore have obvious patient- as well as public health 
benefits, including better prognosis, increased survival, 
prevention of acquisition of further drug resistance, and 
reduced spread of drug resistant strains to vulnerable 
populations.  
In another paper by Nyamagoba et al, also from 
Kenya, the authors indicate high rates of  recurrent TB 
independent of HIV infection, in the western part of the 
country. These observations are in contrast with 
previous studies that have shown HIV infection as a 
risk factor for recurrent TB as well as low rates of 
recurrent TB after curative treatment with short-course 
chemotherapy. Although the current study did not 
expound on the possible reasons including diagnostic, 
and/or treatment issues for these differences, there is 
need for further studies to elucidate this issue for better 
patient management. 
Reports from Nigeria indicate influence of weather 
parameters on the morbidity pattern of pulmonary 
tuberculosis (PTB) in the rain-forest and guinea 
savanna zones of the country.  In their study, Oguntoke 
et al., concluded that intervention strategies for PTB 
control should be sensitive to seasonal characteristics 
for optimum outcomes. 




In sub-Saharan Africa sputum smear microscopy is the 
cornerstone for TB diagnosis especially at peripheral 
health services.  This method is rapid and inexpensive 
and highly specific for Mycobacterium tuberculosis in 
high burden settings. However, it has a limitation of 
low and variable sensitivity, exacerbated in high HIV 
prevalence settings [Elliott AM, et al. 1993]. High TB-
HIV co-infection rates and consequent low TB case 
detection rates impede disease control in many TB 
endemic settings, notably sub-Saharan Africa [WHO 
2011]. In addition, sensitivity is largely determined by 
the duration of microscopic examination. Where 
workloads are high and the amount of time spent 
examining smears is low, further compromising the 
sensitivity [Cambanis A, et al. 2007]. 
In an attempt to collectively and objectively address 
the regional TB threat, two major projects are currently 
being rolled out. In the first, a selected number of new 
genotypic assays which have previously been 
developed to detect resistance faster [WHO 2008 
Catharina C, et al. 2010] than using phenotypic ones, 
have been identified for evaluation of their impact on 
patient important health outcomes in a World Bank 
supported East African Public Health Laboratory 
Networking Project (EAPHNP) involving five 
countries namely Uganda, Tanzania, Rwanda, Burundi 
and Kenya. The overall EAPHLN project objective is 
to support establishment of a network of efficient, high 
quality, accessible public health laboratories for the 
diagnosis and surveillance and of TB and other 
communicable diseases in these countries. In the 
second,  WHO Regional Office for Africa (AFRO) in 
collaboration Kenya Medical Research Institute, 
KEMRI, is currently rolling out a six weeks training 
course on management of joint drug resistant TB and 
collaborative TB and HIV/AIDS activities, in Nairobi, 
Kenya.The overall goal of  the course is to further 
develop the skills especially of officials in charge of 
TB and/or HIV/AIDS control programmes who, 
operating at the national and sub national level, are 
responsible for planning, organizing, implementing and 
evaluating the activities of these programmes in the 
Anglophone speaking countries, based on strategies 
recommended by the World Health Organization. The 
Francophone version was launched in Benin in April 
2011. It is anticipated that outcomes from these 
projects will contribute significantly to policy 
strategies on the management of TB cases in the 
African region. 
References: 
1. The WHO/IUATLD, Global project on anti-
tuberculosis drug resistance surveillance, 
Report No.4, 2007. 
2. World Health Organization (2008).  Anti-
tuberculosis drug resistance in the world 
3. Ministry of Health, Kenya, National Leprosy 
and Tuberculosis control programme (NLTP) . 
Annual Report, 2010. 
4. World Health Organization. Policy Statement: 
Molecular line probe assays for rapid 
screening of patients at risk of multidrug-
resistant tuberculosis (MDRTB). Geneva, 
World Health Organization. 27 June 2008. 
5. WHO, Global Tuberculosis Control: 
Surveillance, Planning, Financing., 2011, 
WHO: Geneva. 
6. Cambanis, A., et al., Investing time in 
microscopy: an opportunity to optimise smear-
based case detection of tuberculosis. Int J 
Tuberc Lung Dis, 2007. 11(1): p. 40-5. 
7. Elliott, A.M., et al., The impact of human 
immunodeficiency virus on presentation and 
diagnosis of tuberculosis in a cohort study in 
Zambia. J Trop Med Hyg, 1993. 96(1): p. 1-
11. 
8. Canetti G, et al. Advances in techniques of 
testing mycobacterial drug sensitivity tests in 
tuberculosis control programs. Bull World 
Health Organ 1969; 41:21-43.  
9. Palomino JC, et al. Rapid culture-based 
methods for drug-resistance detection in 
Mycobacterium tuberculosis. J Microbiol 
Meth, 2008, 75: 161–166. 
10. Catharina C., et al., Rapid Molecular 
Detection of Tuberculosis and Rifampin 
Resistance. New England Journal Med, 2010, 
363(11), 1005–1015.  
 
